首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   2625606篇
  免费   187568篇
  国内免费   8519篇
耳鼻咽喉   34633篇
儿科学   86024篇
妇产科学   72513篇
基础医学   367817篇
口腔科学   70659篇
临床医学   238012篇
内科学   524158篇
皮肤病学   63081篇
神经病学   217018篇
特种医学   101219篇
外国民族医学   737篇
外科学   391333篇
综合类   52453篇
现状与发展   6篇
一般理论   973篇
预防医学   198322篇
眼科学   57277篇
药学   191114篇
  16篇
中国医学   6292篇
肿瘤学   148036篇
  2021年   21687篇
  2019年   21761篇
  2018年   30543篇
  2017年   23566篇
  2016年   27286篇
  2015年   30835篇
  2014年   42169篇
  2013年   62440篇
  2012年   82943篇
  2011年   87322篇
  2010年   52642篇
  2009年   50655篇
  2008年   81314篇
  2007年   85988篇
  2006年   87528篇
  2005年   83602篇
  2004年   80376篇
  2003年   77440篇
  2002年   74591篇
  2001年   129025篇
  2000年   131914篇
  1999年   111078篇
  1998年   31578篇
  1997年   28159篇
  1996年   28453篇
  1995年   27566篇
  1994年   25242篇
  1993年   23556篇
  1992年   85461篇
  1991年   81841篇
  1990年   79023篇
  1989年   76335篇
  1988年   69701篇
  1987年   68211篇
  1986年   63730篇
  1985年   60658篇
  1984年   45075篇
  1983年   38055篇
  1982年   22531篇
  1981年   20044篇
  1979年   39078篇
  1978年   27509篇
  1977年   23323篇
  1976年   21549篇
  1975年   22869篇
  1974年   26868篇
  1973年   25458篇
  1972年   23832篇
  1971年   22028篇
  1970年   20256篇
排序方式: 共有10000条查询结果,搜索用时 17 毫秒
11.
随着婴儿潮、人口老龄化及新技术的广泛应用,人们对听力保健的需求显著增加。在美国,听力保健服务由助听设备专员、耳鼻喉科医生和听力师3类人员提供,其中听力师提供除医疗、手术外宽泛的听力保健服务。美国的听力保健服务体系及听力师教育体系经历了一个渐进的过程:20年前对从业人员的学历要求是听力学硕士,随着对服务质量要求的提高和服务范围的扩大,美国听力师逐渐要求专业博士学位(Au.D),毕业后还需3~4年的专门教育才能成为一名听力师。听力师教育有统一的标准,大学课程要通过听力教育认证委员会(the Accreditation Commission for Audiology Education, ACAE)或学术认证委员会(the Council on Academic Accreditation,CAA)的多程序严格的认证才能被承认。美国听力师需求存在巨大缺口,但是各国听力学教育标准不统一及听力师收入与教育投资不匹配,阻碍了更多的人进入这一领域。美国试图通过改变教育模式,降低教育成本及革新教学方法等改善听力师教育状况,但是听力师教育体系远未完善。  相似文献   
12.
13.

Background

Rosacea is a chronic inflammatory skin condition whose etiology has been linked to mast cells and the antimicrobial peptide cathelicidin LL-37. Individuals with refractory disease have demonstrated clinical benefit with periodic injections of onabotulinum toxin, but the mechanism of action is unknown.

Objectives

To investigate the molecular mechanism by which botulinum toxin improves rosacea lesions.

Methods

Primary human and murine mast cells were pretreated with onabotulinum toxin A or B or control. Mast cell degranulation was evaluated by β-hexosaminidase activity. Expression of botulinum toxin receptor Sv2 was measured by qPCR. The presence of SNAP-25 and VAMP2 was established by immunofluorescence. In vivo rosacea model was established by intradermally injecting LL-37 with or without onabotulinum toxin A pretreatment. Mast cell degranulation was assessed in vivo by histologic counts. Rosacea biomarkers were analyzed by qPCR of mouse skin sections.

Results

Onabotulinum toxin A and B inhibited compound 48/80-induced degranulation of both human and murine mast cells. Expression of Sv2 was established in mouse mast cells. Onabotulinum toxin A and B increased cleaved SNAP-25 and decreased VAMP2 staining in mast cells respectively. In mice, injection of onabotulinum toxin A significantly reduced LL-37-induced skin erythema, mast cell degranulation, and mRNA expression of rosacea biomarkers.

Conclusions

These findings suggest that onabotulinum toxin reduces rosacea-associated skin inflammation by directly inhibiting mast cell degranulation. Periodic applications of onabotulinum toxin may be an effective therapy for refractory rosacea and deserves further study.  相似文献   
14.

Aims

To examine the influence of pre-existing psychiatric disorder on the choice of treatment in patients with gynaecological cancer.

Materials and methods

The analyses were based on all patients who underwent surgical treatment for endometrial, ovarian or cervical cancer who were registered in the Danish Gynecological Cancer Database in the years 2007–2014 (3059 patients with ovarian cancer, 5100 patients with endometrial cancer and 1150 with cervical cancer). Logistic regression model and Cox regression model, adjusted for relevant confounders, were used to estimate the effect of pre-existing psychiatric disorder on the course of cancer treatment. Our outcomes were (i) presurgical oncological treatment, (ii) macroradical surgery for patients with ovarian cancer, (iii) radiation/chemotherapy within 30 days and 100 days after surgery and (iv) time from surgery to first oncological treatment.

Results

In the group of patients with ovarian cancer, more patients with a psychiatric disorder received macroradical surgery versus patients without a psychiatric disorder, corresponding to an adjusted odds ratio of 1.24 (95% confidence interval 0.62–2.41) and the chance for having oncological treatment within 100 days was odds ratio = 1.26 (95% confidence interval 0.77–2.10). As for patients with endometrial cancer, all outcome estimates were close to unity. The adjusted odds ratio for oncological treatment within 30 days after surgery in patients with cervical cancer with a history of psychiatric disorder was 0.20 (95% confidence interval 0.03–1.54).

Conclusions

We did not find any significant differences in the treatment of ovarian and endometrial cancer in patients with pre-existing psychiatric diagnoses. When it comes to oncological treatment, we suggest that increased attention should be paid to patients with cervical cancer having a pre-existing psychiatric diagnosis.  相似文献   
15.

Background

Total knee arthroplasty is a treatment option for debilitating arthritis. In the postoperative period, patients experience moderate to severe pain affecting the rehabilitation, hospital stay, and patient satisfaction. This study aims at utilizing current best evidence to determine whether adductor canal block (ACB) or periarticular injection (PAI) is a better modality for managing short-term postoperative pain and opioid consumption.

Methods

Embase, MEDLINE, HealthStar, Emcare, and PubMed were searched for randomized controlled trials from 1946 to August 2018, for literature addressing the comparison of ACB and PAI for pain management in the setting of total knee arthroplasty. A systematic review and meta-analysis were performed.

Results

Six studies were included in our meta-analysis. When examining the combined visual analog scale (VAS) pain values for each group, analysis demonstrated greater reduction in scores for the PAI group, and the difference was statistically significant (P = .001). When comparing the VAS scores of subgroups analyzed at specific periods in time, there was a trend toward lower VAS scores in subgroups analyzed at 24 hours and 48 hours postoperatively (at rest and at movement) in the PAI group. Overall opioid consumption was lower in the PAI group, with demonstrated statistical significance (P = .03). When comparing the postoperative subgroups, there was a trend toward decreased opioid use in the PAI group, with 13.25% less opioid use at 48 hours and 9.5% less opioid use at 24 hours.

Conclusion

PAI could significantly improve postoperative pain and opioid consumption when compared with ACB. Additional, high-quality studies are required to further address this topic.  相似文献   
16.
Abstract

This study is a single-center, retrospective analysis of postmenopausal women presenting with dyspareunia and vulvar pain, aiming to evaluate relative effectiveness of vestibular CO2 laser therapy as a treatment. Three monthly sessions of laser were performed to each patient and thereafter a three-months follow-up was stablished. A total number of 72 patients undergoing vestibular laser treatment were recruited from patient files in the period between 2016 and 2018. Among these, 39 women also received a concomitant treatment with ospemifene (60?mg/day) during the study period. There was a statistically significant reduction of all the symptoms in both groups up to the three month follow-up. Regarding dryness and dyspareunia, the relief tent to be more prominent in the ospemifene?+?laser group at all follow-ups and remained statistically significant at three-month follow-up. Specifically, vestibular dryness was significantly lower in the ospemifene?+?laser group compared with the laser treatment group (?87% vs???34%, respectively), and the vestibular health score started declining faster in the ospemifene?+?laser group. Although, additional research is needed to understand the mechanism of action, our data shows that a combination regimen of laser and ospemifene may improve clinical effectiveness for long-term treatment of symptoms associated with the under-recognized genitourinary syndrome of menopause.  相似文献   
17.
18.
19.
20.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号